SS Innovations International (NASDAQ: SSII) has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital in Ahmedabad, India. The program commenced with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra 3.0 system. This development underscores the increasing adoption of robotic-assisted cardiac surgery in emerging markets and positions SS Innovations as a key player in the global surgical robotics arena.
The procedure marks a significant milestone for SS Innovations, as it demonstrates the versatility and efficacy of the SSi Mantra system in complex cardiac interventions. The company reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025, with installations now spanning 12 countries, including recent expansions into Colombia, Sri Lanka, and the Philippines. This growth trajectory highlights the accelerating demand for robotic surgical solutions worldwide, particularly in regions where access to advanced minimally invasive techniques has been limited.
The launch of the robotic cardiac surgery program at HCG Hospital is important because it signifies the broadening application of the SSi Mantra beyond general surgery into specialized cardiac procedures, which require high precision and advanced robotic capabilities. Cardiac surgery is among the most complex surgical disciplines, and the successful performance of a LIMA take-down—a critical step in coronary artery bypass grafting—using the SSi Mantra system validates its potential to improve patient outcomes through smaller incisions, reduced trauma, and faster recovery times. For patients in India and surrounding regions, this means greater access to cutting-edge surgical care that was previously available only in select global centers.
SS Innovations is actively pursuing U.S. Food and Drug Administration (FDA) review and European Union CE marking for the SSi Mantra, aiming to enter additional international markets. Regulatory approvals in these major markets would significantly amplify the company's addressable market and competitive standing against established robotic surgery platforms. The expansion into cardiac surgery at a reputable institution like HCG Hospital also serves as a clinical reference that could accelerate adoption in other hospitals across India and beyond. As the company continues to grow its installed base—now at 238 systems—and enters new geographies, it is well-positioned to capitalize on the global shift toward robotic-assisted surgery. For more details on this development, see the full announcement on www.newmediawire.com. The company's latest news and updates are available in its newsroom at https://ibn.fm/SSII, and a detailed client profile can be found at SS Innovations International (NASDAQ: SSII). Forward-looking statements and disclaimers are provided on the InvestorBrandNetwork website at https://IBN.ai/Disclaimer.
